Co-Diagnostics, Inc. (CODX)

USD 0.34

(0.84%)

Market Cap (In USD)

11.3 Million

Revenue (In USD)

6.81 Million

Net Income (In USD)

-35.33 Million

Avg. Volume

194.4 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.7175-2.23
PE
-0.27
EPS
-1.24
Beta Value
-0.846
ISIN
US1897631057
CUSIP
189763105
CIK
1692415
Shares
33572600.0
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Medical - Devices
CEO
Mr. Dwight H. Egan
Employee Count
-
Website
https://www.codiagnostics.com
Ipo Date
2017-07-12
Details
Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. It offers polymerase chain reaction (PCR) diagnostic tests for COVID-19, tuberculosis, hepatitis B and C, human papilloma virus, malaria, chikungunya, dengue, and the zika virus; three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; and molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. The company also provides tests that identify genetic traits in plant and animal genomes; and portable PCR device designed to bring PCR to patients in point-of-care and at-home settings. In addition, it intends to sell diagnostic equipment from other manufacturers as self-contained lab systems. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.